Frank Jaksch

Online opportunities — not loss of big account — drove finished products shift, ChromaDex CEO claims

21-Aug-2017 By Hank Schultz

A shift in market dynamics — not a legal dispute with a key customer — is what drove ChromaDex to try for a second time the finished products route for one of its branded ingredients.

ChromaDex CEO says new NDI guidance could be tool to clean up marketplace

12-Oct-2016 By Hank Schultz

The NDI draft guidance offers a workable road map for companies willing to provide the safety information already called for by law, according to one ingredient supplier.

Crisis plan needs to extend to financial risk too, ChromaDex learns

07-Jul-2016 By Hank Schultz

Having a crisis communications plan in place to deal with allegations of financial impropriety is a must for a public company, as ChromaDex Corp recently learned to its chagrin.

ChromaDex extends earnings streak, cuts losses in half

20-May-2015 By Hank Schultz

ChromaDex Corp. notched its fourth consecutive quarter of record earnings with its Q1 2015 earnings report which it made public this week. The company reported net sales of $5.3 million, an increase of 71% year-over-year. The company also halved its net...

Corporate restructuring called for to alleviate persistent practice of lab shopping

21-Apr-2014 By Hank Schultz

Dry labbing and lab shopping are problems that persist in the dietary supplements industry, according to Frank Jaksch, CEO of ChromaDex.  It is still all too easy for a company to get the results it wants, he said at a recent conference.

ChromaDex signs $62 million deal for Niagen, Purenergy ingredients

07-Jan-2014 By Hank Schultz

ChromaDex has announced the largest deal in its history, a $62 million agreement with nework marketing company 5LINX that covers its Niagen and Purenergy ingredients.

Study shows potential for D-tagatose as sports nutrition ingredient

30-Jul-2013 By Hank Schultz

D-tagatose, an alternative sweetener that has drifted at the periphery of commercial viability for more than a decade, may have a new lease on life because of its blood sugar management properties, according to a study conducted by ChromaDex.

GMP compliance is a 'huge opportunity' for dietary supplements market: Chromadex CEO

07-Mar-2013 By Stephen Daniells in Irvine, CA

FDA enforcement of the current good manufacturing practices (cGMP) regulations is ‘a huge opportunity for the dietary supplements market’, says Frank Jaksch, CEO of Chromadex.

Chromadex sells BluScience retail supplement line to Canadian marketing firm

26-Feb-2013 By Hank Schultz

Chromadex has announced the sale of its BluScience retail line of supplements to NeutriSci International, a private nutraceutical and cosmetic product marketing and brand development firm based in Calgary, Alberta.

Dry labbing practices ‘mushrooming’ and ‘metamorphosing’: Chromadex CEO

16-Nov-2012 By Stephen Daniells

The practice of dry labbing in the industry is continuing, and the practice is becoming more sophisticated, increasing the need for continued vigilance, says Frank Jaksch, CEO of Chromadex.

Chromadex to develop validated analytical tests for milk thistle, turmeric

31-Oct-2012 By Hank Schultz

Chromadex will develop create single laboratory validated methods for the quantitative determination of total silymarin content of milk thistle and of total curcuminoid content in turmeric under a government contract, the company announced Monday.

ChromaDex slips into profit in first quarter

19-May-2010 By staff reporter

ChromaDex is optimistic about its stronghold in the food and supplement sector following a strong first quarter, which saw a revenue increase of 34 percent.

DSHEA turns 15

The devil in GMP details

23-Dec-2009 By Shane Starling

In the fifth and final installment of this DSHEA special, Frank Jaksch, the president and chief executive officer of Californian-based botanicals reference provider, Chromadex, outlines why he thinks current GMP inspection methodologies are unlikely to...

Antioxidants-by-fermentation: One step closer to market

12-Jun-2009 By Lorraine Heller

ChromaDex has received a grant to further develop a technology that can create anthocyanins via fermentation, which the firm says will allow it to test whether the process is viable on a commercial scale.